Contents

Highlights of This Issue 6367

SPECIAL FEATURES

CCR Translations

6369 Therapeutic Oligonucleotides: The Road Not Taken
Cy A. Stein and Sanjay Goel
See commentary p. 6582

6373 The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression
Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas

6381 TLX1-Induced T-cell Acute Lymphoblastic Leukemia
Kim De Keersmaecker and Adolfo A. Ferrando

Molecular Pathways

CCR Focus

6388 Antibody Conjugates: The Future Is Now
Susan E. Bates

6389 Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher and Ravi V.J. Chari

6398 Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman and Ira Pastan

6406 Antibody-Radiouclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner and Dario Neri

6417 Antibody-Drug Conjugates of Calicheamicin Derivative: Gentuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart

6428 Brentuximab Vedotin (SGN-35)
Jessica Katz, John E. Janik, and Anas Younes

CANCER THERAPY: PRECLINICAL

6437 Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
Patricia M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish, and Mark X. Slawkowski

6448 SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz, and John M. Lambert

Review

6459 Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC
René H. Medema, Chia-Chi Lin, and James Chih-Hsin Yang

6467 Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism
Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Hu, and Bernard A. Fox

6482 Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin, Tianyin Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball

6490 The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
**CANCER THERAPY: CLINICAL**

**Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin**
Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shippe-Spotoe, David R. Gandara, Alice Chen, and John M. Kirkwood

**A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer**

See article p. 6369

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

**Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials**
Ming-Wen An, Sumithra J. Mandrekar, Megan E. Branda, Shauna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent
LETTERS TO THE EDITOR

KRAS rs61764370 in Epithelial Ovarian Cancer–Letter
Joanne B. Weidhaas and Frank J. Slack

KRAS rs61764370 in Epithelial Ovarian Cancer–Response
Harvey A. Risch, Andrew Berchuck, and Paul D.P. Pharoah; for the Ovarian Cancer Association Consortium

ABOUT THE COVER

The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vargatef, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vargatef combination, even in patients with mutant KRAS. For details, see the article by Poindessous and colleagues on page 6522 of this issue.